Biogen Message Board - Msg: 3211737

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biogen

BIIB 181.93

+2.9%

Nov 25 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (545)	1/20/1998 2:54:00 PM
From: Vector1	Read Replies (1) of 1686

Rick, Some of the analysts are starting to pick up on the potential to the CD40 MAB. The following is from Matt Geller's of Oppenheimers recent report: -- CD40 and its ligand mediate communication between T-cells and B-cells and are required for antibody production by B cells. Biogen's humanized antibody to CD40 ligand is designed to disrupt this interaction and could be useful as a therapeutic for disorders marked by inappropriate antibody production. ú A phase I safety and proof-of-concept study for ITP (immune thrombocytopenic purpura), a disease in which patients produce antibodies to their own platelets, is now complete. ú The ultimate target for the anti-CD40 ligand antibody is patients with lupus, an autoimmune disease marked by production of a variety of autoantibodies. There are 250,000 to 1 million individuals in the U.S. with lupus. A phase IIb trial for lupus is expected to commence in Q3. Humanized Antibody to CD40 Ligand

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next